Abstract
Fecal microbiota transplantation (FMT) has demonstrated efficacy in treating inflammatory bowel diseases and irritable bowel syndrome in an increasing number of randomized controlled trials. Recently published data gives striking insights into the factors associated with FMT success paving the road for the use of precision medicine in gastrointestinal disorders.
Highlights
Fecal microbiota transplantation (FMT) has demonstrated efficacy in treating inflammatory bowel diseases and irritable bowel syndrome in an increasing number of randomized controlled trials
Inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS) are associated with alteration of the gut microbiota, which contributes to disease onset and maintenance
Published data has given insights into the factors associated with fecal microbiota transplantation (FMT) efficacy, paving the road for precision medicine in its use in gastrointestinal disorders
Summary
Fecal microbiota transplantation (FMT) has demonstrated efficacy in treating inflammatory bowel diseases and irritable bowel syndrome in an increasing number of randomized controlled trials. Inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS) are associated with alteration of the gut microbiota, which contributes to disease onset and maintenance. * Correspondence: harry.sokol@aphp.fr 3French Group of Fecal Microbiota Transplantation (GFTF; www.gftf.f), Paris, France 4Gastroenterology Department, Saint Antoine Hospital, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, F-75012 Paris, France Full list of author information is available at the end of the article
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
